(Q44369477)

English

The N-terminal region of the human papillomavirus L2 protein contains overlapping binding sites for neutralizing, cross-neutralizing and non-neutralizing antibodies

scientific article published on 11 November 2010

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

2 December 2017

The N-terminal region of the human papillomavirus L2 protein contains overlapping binding sites for neutralizing, cross-neutralizing and non-neutralizing antibodies (English)

1 reference

Europe PubMed Central

PubMed publication ID

2 December 2017

1 reference

based on heuristic

inferred from title

author name string

Ivonne Rubio

1

1 reference

Europe PubMed Central

PubMed publication ID

2 December 2017

Hanna Seitz

2

1 reference

Europe PubMed Central

PubMed publication ID

2 December 2017

Elena Canali

3

1 reference

Europe PubMed Central

PubMed publication ID

2 December 2017

Peter Sehr

4

1 reference

Europe PubMed Central

PubMed publication ID

2 December 2017

Angelo Bolchi

5

1 reference

Europe PubMed Central

PubMed publication ID

2 December 2017

Massimo Tommasino

6

1 reference

Europe PubMed Central

PubMed publication ID

2 December 2017

Simone Ottonello

7

1 reference

Europe PubMed Central

PubMed publication ID

2 December 2017

Martin Müller

8

1 reference

Europe PubMed Central

PubMed publication ID

2 December 2017

language of work or name

0 references

publication date

11 November 2010

1 reference

Europe PubMed Central

PubMed publication ID

2 December 2017

1 reference

Europe PubMed Central

PubMed publication ID

2 December 2017

409

1 reference

Europe PubMed Central

PubMed publication ID

2 December 2017

2

1 reference

Europe PubMed Central

PubMed publication ID

2 December 2017

348-359

1 reference

Europe PubMed Central

PubMed publication ID

2 December 2017

Protection against heterologous human papillomavirus challenge by a synthetic lipopeptide vaccine containing a broadly cross-neutralizing epitope of L2.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2010.10.017

7 January 2021

Effect of prophylactic human papillomavirus L1 virus-like-particle vaccine on risk of cervical intraepithelial neoplasia grade 2, grade 3, and adenocarcinoma in situ: a combined analysis of four randomised clinical trials

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2010.10.017

7 January 2021

Human papillomavirus vaccines and the potential for cross-protection between related HPV types

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2010.10.017

7 January 2021

Interaction of tSNARE syntaxin 18 with the papillomavirus minor capsid protein mediates infection

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2010.10.017

7 January 2021

Two highly conserved cysteine residues in HPV16 L2 form an intramolecular disulfide bond and are critical for infectivity in human keratinocytes

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2010.10.017

7 January 2021

Monoclonal antibodies to HPV-6 L1 virus-like particles identify conformational and linear neutralizing epitopes on HPV-11 in addition to type-specific epitopes on HPV-6.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2010.10.017

7 January 2021

Hybrid papillomavirus L1 molecules assemble into virus-like particles that reconstitute conformational epitopes and induce neutralizing antibodies to distinct HPV types

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2010.10.017

7 January 2021

Identification of two cross-neutralizing linear epitopes within the L1 major capsid protein of human papillomaviruses

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2010.10.017

7 January 2021

Mechanisms of human papillomavirus type 16 neutralization by l2 cross-neutralizing and l1 type-specific antibodies

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2010.10.017

7 January 2021

Heparan sulfate-independent cell binding and infection with furin-precleaved papillomavirus capsids

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2010.10.017

7 January 2021

Protection of rabbits against challenge with rabbit papillomaviruses by immunization with the N terminus of human papillomavirus type 16 minor capsid antigen L2.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2010.10.017

7 January 2021

A protective and broadly cross-neutralizing epitope of human papillomavirus L2.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2010.10.017

7 January 2021

Quadrivalent vaccine against human papillomavirus to prevent anogenital diseases

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2010.10.017

7 January 2021

Sustained efficacy up to 4.5 years of a bivalent L1 virus-like particle vaccine against human papillomavirus types 16 and 18: follow-up from a randomised control trial

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2010.10.017

7 January 2021

Concatenated multitype L2 fusion proteins as candidate prophylactic pan-human papillomavirus vaccines

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2010.10.017

7 January 2021

Nasal immunization of mice with peptide having a cross-neutralization epitope on minor capsid protein L2 of human papillomavirus type 16 elicit systemic and mucosal antibodies

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2010.10.017

7 January 2021

Safety and immunogenicity of a peptide containing the cross-neutralization epitope of HPV16 L2 administered nasally in healthy volunteers

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2010.10.017

7 January 2021

Neutralization of HPV16, 18, 31, and 58 pseudovirions with antisera induced by immunizing rabbits with synthetic peptides representing segments of the HPV16 minor capsid protein L2 surface region

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2010.10.017

7 January 2021

Modification of human papillomavirus-like particle vaccine by insertion of the cross-reactive L2-epitopes

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2010.10.017

7 January 2021

Bovine papillomavirus type 1 infection is mediated by SNARE syntaxin 18

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2010.10.017

7 January 2021

Epidemiologic classification of human papillomavirus types associated with cervical cancer

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2010.10.017

7 January 2021

Efficacy of a prophylactic adjuvanted bivalent L1 virus-like-particle vaccine against infection with human papillomavirus types 16 and 18 in young women: an interim analysis of a phase III double-blind, randomised controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2010.10.017

7 January 2021

Efficacy of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by oncogenic HPV types (PATRICIA): final analysis of a double-blind, randomised study in young women

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2010.10.017

7 January 2021

Cross-neutralization of cutaneous and mucosal Papillomavirus types with anti-sera to the amino terminus of L2.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2010.10.017

7 January 2021

Cleavage of the papillomavirus minor capsid protein, L2, at a furin consensus site is necessary for infection

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2010.10.017

7 January 2021

Reactivity pattern of 92 monoclonal antibodies with 15 human papillomavirus types

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2010.10.017

7 January 2021

Potent anti-HPV immune responses induced by tandem repeats of the HPV16 L2 (20 -- 38) peptide displayed on bacterial thioredoxin

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2010.10.017

7 January 2021

Chimeric L1-L2 virus-like particles as potential broad-spectrum human papillomavirus vaccines

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2010.10.017

7 January 2021

A generic capture ELISA for recombinant proteins fused to glutathione S-transferase: validation for HPV serology

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2010.10.017

7 January 2021

A papillomavirus-like particle (VLP) vaccine displaying HPV16 L2 epitopes induces cross-neutralizing antibodies to HPV11.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2010.10.017

7 January 2021

Common neutralization epitope in minor capsid protein L2 of human papillomavirus types 16 and 6

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2010.10.017

7 January 2021

Identifiers

10.1016/J.VIROL.2010.10.017

1 reference

Europe PubMed Central

PubMed publication ID

2 December 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

2 December 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q44369477&oldid=2020194326"